←
James O'Neill219 posts
James O'Neill avatar

James O'Neill

@jamieroneill

Higher Trainee in Forensic Psychiatry. Research interest in clinical psychopharmacology.

◷ Joined June 2012▧ 7 Photos and videos
Mark Horowitz @markhoro.bsky.social avatar
⟳ James O'Neill retweeted
Mark Horowitz @markhoro.bsky.social@markhoro·Sep 18

We find that stopping antipsychotic depots abruptly in @SchizBulletin Open is likely to produce too rapid a shift in drug levels to avoid withdrawal effects (which might provoke relapse), despite being much slower than stopping oral medication. This is contrary to the general wisdom that depots are 'self-tapering' on stopping. 6-monthly paliperidone might be an exception. Instead it makes more sense to taper depots to lowest dose and then switch to oral medications for a more careful taper. Led by industrious @jamieroneill. Link below.

Post attachment
James O'Neill avatar
James O'Neill@jamieroneill·11 Sep 2025

Great to work with @markhoro @_AndersSorensen & @DavidTa23968240 on this in silico analysis of antidepressants. Dosing in smaller amounts but more often reduces fluctuations in the body and the risk of withdrawal effects. Thanks to JAD and @ElsevierConnect for publishing!

Good to see the final version of this paper in print from @jamieroneill Tapering drugs by dosing every second day risks severe withdrawal effects and is generally not wise. Better to use smaller doses e.g. liquids or compounded versions each day bit.ly/46i0Pvp

Post attachment
Mark Horowitz @markhoro.bsky.social avatar
⟳ James O'Neill retweeted
Mark Horowitz @markhoro.bsky.social@markhoro·12 Sep 2024

Clinically useful paper led by @jamieroneill looking at how to hyperbolically taper decanoate antipsychotic depots. Abrupt stopping likely not sufficiently slow enough taper for many patients, requires switching to orals bit.ly/3BbaDew with @ @DavidTa23968240

James O'Neill avatar
James O'Neill@jamieroneill·27 Aug 2024

Thanks to @PsychTimes for writing about our recent paper in Journal of Psychopharmacology on what clinicians should consider when increasing the dose of antipsychotics @adamjameson96 @DrSamMcLean @ChrisL8888 psychiatrictimes.com/view/an…

Mark Horowitz @markhoro.bsky.social avatar
⟳ James O'Neill retweeted
Mark Horowitz @markhoro.bsky.social@markhoro·18 Jun 2024

Glad to have had the opportunity to talk at the conference about deprescribing to a packed room (a friend of mine was turned away at the door!) and many thoughtful and engaged questions. Thanks to @DavidTa23968240 and Robin Murray for chairing

Day 2 of #RCPsychIC so far: two thought-provoking symposia, on psychotropic deprescribing and the evidence for antidepressants. Featuring @DavidTa23968240, @markhoro, @joannamoncrieff and @GlynLewis9 and chaired by Prof Sirs Murray and Wessley #RCPsych #choosepsychiatry

Post attachment
Dr Evgeny Legedin 🇷🇺 avatar
⟳ James O'Neill retweeted
Dr Evgeny Legedin 🇷🇺@DrEvgenyLegedin·18 Jun 2024

Prof Taylor from King's College London recommends that antidepressants are regularly reviewed and, if no longer necessary, tapered in a manner proportional to their current dose (so that reductions get smaller and smaller in size as the total dose gets smaller). #RCPSychIC 2024

Post attachmentPost attachmentPost attachmentPost attachment
James O'Neill avatar
James O'Neill@jamieroneill·18 Mar 2024

Dosing to individual response vital, and drug monitoring / pharmacogenetics plays key role in personalising dosing. This should be used if clinical response not achieved by our recommended targets to see if either increase or switch needed @DrSamMcLean @adamjameson96 @ChrisL8888

James O'Neill avatar
James O'Neill@jamieroneill·18 Mar 2024

New paper out in Journal of Psychopharmacology BNF maximum doses for psychosis drugs based on safety, not efficacy. Not for use as guideline / target to achieve clinical response. Point of futility often much lower @DrSamMcLean @adamjameson96 @ChrisL8888 journals.sagepub.com/doi/10.…

Sarah Jones avatar
⟳ James O'Neill retweeted
Sarah Jones@SarahJPharm·25 Feb 2024

Dear @NHSKFH, any chance the new Maudsley Deprescribing Guidelines could be added to your excellent eBook collection alongside the Maudsley Prescribing Guidelines? Lots of HCPs would be delighted to have access to this new resource.

The Maudsley Deprescribing Guidelines is available in the UK amzn.to/40o3wrI, US amzn.to/3tTQq9s, Australia bit.ly/3OKZ9m7 Canada bit.ly/3uB4Zj9and elsewhere around the world (also at other booksellers).

Post attachment